BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20972242)

  • 21. Expression profile and prognostic value of glypican-3 in post-operative South Korean hepatocellular carcinoma patients.
    Jeon Y; Kim H; Jang ES; Hong S; Kim JW; Yoon YS; Cho JY; Han HS; Jeong SH
    APMIS; 2016 Mar; 124(3):208-15. PubMed ID: 26764243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival impact of capsule rupture in stage I clear cell carcinoma of the ovary in comparison with other histological types.
    Higashi M; Kajiyama H; Shibata K; Mizuno M; Mizuno K; Hosono S; Kawai M; Nakanishi T; Nagasaka T; Kikkawa F
    Gynecol Oncol; 2011 Dec; 123(3):474-8. PubMed ID: 21955484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clear cell carcinomas of the ovary: a multi-institutional study of 129 cases in Korea with prognostic significance of Emi1 and Galectin-3.
    Min KW; Park MH; Hong SR; Lee H; Kwon SY; Hong SH; Joo HJ; Park IA; An HJ; Suh KS; Oh HK; Yoo CW; Kim MJ; Chang HK; Jun SY; Yoon HK; Chang ED; Kim DW; Kim I;
    Int J Gynecol Pathol; 2013 Jan; 32(1):3-14. PubMed ID: 23202783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary.
    Kim A; Serada S; Enomoto T; Naka T
    Expert Opin Ther Targets; 2010 Sep; 14(9):963-71. PubMed ID: 20673185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of CXCR4 indicates poor prognosis in patients with clear cell carcinoma of the ovary.
    Sekiya R; Kajiyama H; Sakai K; Umezu T; Mizuno M; Shibata K; Yamamoto E; Fujiwara S; Nagasaka T; Kikkawa F
    Hum Pathol; 2012 Jun; 43(6):904-10. PubMed ID: 22169254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
    Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
    Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
    Davidson B; Trope' CG; Wang TL; Shih IeM
    Gynecol Oncol; 2006 Dec; 103(3):814-9. PubMed ID: 16844205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma.
    Ofuji K; Saito K; Suzuki S; Shimomura M; Shirakawa H; Nobuoka D; Sawada Y; Yoshimura M; Tsuchiya N; Takahashi M; Yoshikawa T; Tada Y; Konishi M; Takahashi S; Gotohda N; Nakamoto Y; Nakatsura T
    Oncotarget; 2017 Jun; 8(23):37835-37844. PubMed ID: 28035063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
    Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A
    Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports.
    Suzuki S; Shibata K; Kikkawa F; Nakatsura T
    Hum Vaccin Immunother; 2014; 10(2):338-43. PubMed ID: 24252799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ARID1A expression in ovarian clear cell carcinoma with an adenofibromatous component.
    Nishikimi K; Kiyokawa T; Tate S; Iwamoto M; Shozu M
    Histopathology; 2015 Dec; 67(6):866-71. PubMed ID: 25913291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clear cell carcinoma of the ovary: is there a role of histology-specific treatment?
    Takano M; Tsuda H; Sugiyama T
    J Exp Clin Cancer Res; 2012 Jun; 31(1):53. PubMed ID: 22655678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas.
    Nishimura S; Tsuda H; Ito K; Takano M; Terai Y; Jobo T; Kigawa J; Sugiyama T; Yaegashi N; Aoki D
    Int J Gynecol Cancer; 2010 Feb; 20(2):220-6. PubMed ID: 20134266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The association of taxane resistance genes with the clinical course of ovarian carcinoma.
    Ehrlichova M; Mohelnikova-Duchonova B; Hrdy J; Brynychova V; Mrhalova M; Kodet R; Rob L; Pluta M; Gut I; Soucek P; Vaclavikova R
    Genomics; 2013 Aug; 102(2):96-101. PubMed ID: 23542236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High glypican-3 expression characterizes a distinct subset of ovarian clear cell carcinomas in Canadian patients: an opportunity for targeted therapy.
    Wiedemeyer K; Köbel M; Koelkebeck H; Xiao Z; Vashisht K
    Hum Pathol; 2020 Apr; 98():56-63. PubMed ID: 32017945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial.
    Timmers PJ; Zwinderman AH; Teodorovic I; Vergote I; Trimbos JB
    Int J Gynecol Cancer; 2009 Jan; 19(1):88-93. PubMed ID: 19258948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of Glypican 3 in low and high grade urothelial carcinomas.
    Aydin O; Yildiz L; Baris S; Dundar C; Karagoz F
    Diagn Pathol; 2015 Apr; 10():34. PubMed ID: 25896897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of podoplanin in epithelial ovarian carcinomas and its potential as a marker for clear cell adenocarcinoma.
    Oe S; Hasegawa K; Nagase S; Kato R; Torii Y; Udagawa Y
    Int J Gynecol Pathol; 2010 Sep; 29(5):405-10. PubMed ID: 20736762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma.
    Eisenhauer EL; Sonoda Y; Levine DA; Abu-Rustum NR; Gemignani ML; Sabbatini PJ; Barakat RR; Chi DS
    Am J Obstet Gynecol; 2008 Feb; 198(2):213.e1-7. PubMed ID: 18226627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glypican-3 expression in primary and recurrent ovarian carcinomas.
    Stadlmann S; Gueth U; Baumhoer D; Moch H; Terracciano L; Singer G
    Int J Gynecol Pathol; 2007 Jul; 26(3):341-4. PubMed ID: 17581422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.